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Cancer stem cells (CSCs) may be responsible for tumor recurrence.
Metabolic labelling of newly synthesized proteins with non-canonical
amino acids allows us to discriminate CSCs in mixed populations
due to the quiescent nature of these cells.
Cancer stem cells (CSCs) exist in low population in primary
tumor and cell lines. These cells can undergo self-renewal or
differentiation into all the cell types seen in bulk tumors.1
CSCs are resistant to chemo- and radiotherapies and thus
might cause tumor recurrence. A better understanding of the
proteome of these cells might offer a promising way to identify
marker and therapeutic target. At present, most of proteomic
studies of CSCs focus on glioblastoma stem cells because they
have a well-established in vitro adherence culture model,2–5
which is not available in other cancer types.6 Otherwise,
isolation of CSCs population via fluorescence activated cell
sorting (FACS) from primary tumors or cell lines is necessary.7,8
Therefore, developing a labelling method for discrimination of
CSCs in a heterogeneous population while compatible with
downstream proteomics analysis is highly desirable.
CSCs share the property of slow cycling with stem cells,9
which generally have an extended G0 (quiescent) phase, and
the rate of de novo synthesis of protein is lower than for other
phases.10 Because of the lower rate of cellular protein synthesis
in CSCs, using pulse-labeling to label the newly synthesized
proteins in mixed populations, non-CSCs will be labelled
faster than CSCs. Conventional pulse-labeling method uses
radioactive 35S-methionine.11 Recently, a large number of
noncanonical amino acids (ncAAs) have been incorporated
into cells site-specifically or residue-specifically,12,13 and served
as powerful tools for protein engineering and tagging.14–23 As
one of the most widely used methods, methionine analogues
with side chains containing azide and alkyne groups have been
employed as substrates for the natural translational machinery
of cells.24,25 Compared to radioactive 35S-methionine, these
analogues can undergo bioorthogonal ligation reaction, which
allows further introduction of additional functionalities for
downstream proteomics analysis of proteome.22 For example,
we previously have shown that coumarin based fluorogenic
dye and reactive methionine analogue homopropargylglycine
(HPG) could be used to investigate the spatial and temporal
features of protein synthesis in E coli and mammalian cells by
cell imaging.21,23
In this proof of concept study, as shown in Scheme 1,
metabolic incorporation of HPG has been used to distinguish
CSCs and non-CSCs in a heterogeneous population by controlling
the incorporation time of HPG. Cell staining with fluorescent dye
was used to monitor cell population changes via flow cytometry.
By using 3-azido-7-hydroxycoumarin and azido cyanine5 to
react with the alkyne group in HPG though copper(I) catalyzed
alkyne–azide cycloaddition (CuAAC) reaction,26,27 the successful
incorporation of HPG in model cell line HCT-116 was confirmed
by fluorescent microscopy and flow cytometry. Non-CSCs show
distinctly higher fluorescence intensity than CSCs, which is due
to a lower rate of protein synthesis in CSCs. Co-staining HPG
with CSCs maker CD133 further confirmed the population with
low HPG incorporation is the CSC population. For living cell
applications, the potential cytotoxicity of copper is a major
Scheme 1 (a) Schematic representation of discrimination of colon
cancer stem cells using noncanonical amino acid. (b) Cu(I) catalysed
alkyne-azide cycloaddition (CuAAC) reaction between HPG with
3-azido-7-hydroxycoumarin and azido cyanine5 (Cy5-Azide).
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concern, however, the Cu(II)-bis-L-histidine complex used in
our study shows low cytotoxicity.28 In addition, we are seeking
the possibility of new copper-free reaction conditions for living
cells labelling.29,30
Initially, we tested HPG incorporation in colon cancer cell
line HCT-116 by fluorescence microscopy. It has been
reported that HCT-116 has CSCs subpopulations, which can
be isolated by using well-studied CSCs maker CD133 and
aldehyde dehydrogenase (ALDH) enzyme activity assay.31,32
Incorporation of HPG in this model cell line was visualized
by using 3-azido-7-hydroxycoumarin. The fluorescence of
fluorophore in 3-azido-7-hydroxycoumarin is quenched by
the azide group and will recover after the CuAAC reaction
upon the formation of the triazole ring.26,33 This fluorogenic
nature ensures low background and high signal/noise ratio of
the detection.21,23,34–36 Compared to the Met control, as
expected, HPG treated cells emit bright fluorescence (Fig. 1).
These images indicate HPG can be successfully metabolically
incorporated in our model cell line HCT-116.
To determine the difference of metabolic incorporation of
HPG in the CSCs and non-CSCs population, these two
populations were isolated by using a combination of CD133
and ALDEFLUOR assay, which can detect ALDH enzyme
activity in living cells.37 In general, the ALDH+CD133+ cells
are considered as enriched in CSCs population. As shown in
Fig. 2, the ALDHCD133 (i.e. non-CSC) population shows
more fluorescent cells than the ALDH+CD133+ (i.e. CSCs)
population. Based on the microcopy images, fluorescent cells
have been counted and summed in both populations (Fig. 2g).
Results indicate the rate of metabolic incorporation of HPG in
CSCs is much slower than non-CSCs.
Based on the above results, the HPG positive population
was determined using flow cytometry at different labeling time
points. Cells growing at the log phase were used for the HPG
labeling experiment in order to reduce the influence of the
cell–cell contact and obtain an appropriate amount of cells for
down-stream studies. To achieve this, cells were seeded as
single cell suspensions 12 h before labeling at a seeding density
of estimated 50% coverage of culture surface. Fig. 3a shows an
overlap between HPG (green line) and L-Met (red histogram) and
HPG with protein synthesis inhibitor anisomycin16 (black line)
treated cells, which indicate the existence of HPG negative
population (30%) in HCT-116. To confirm this HPG negative
population only related to the protein synthesis rate of these
cells, we doubled the HPG incubation time. As shown in
Fig. 3b, the HPG negative population then decreased to less
than 3%. According to our results (Fig. S1, ESIw) and
literature reports,31 the CSCs proportion in HCT-116 should
be around 10–30%, as evaluated by CD133 antibody staining
or ALDEFLUOR assay. Our results indicate that by simply
changing the incubation time, we can label the whole population
(4 h incubation) or only non-CSCs (2 h incubation). To further
confirm the HPG negative population (after 2 h incubation)
corresponds to the CSCs, we conducted the co-staining of HPG
and the CSCs marker CD133. Fig. 4 shows CD133 positive
Fig. 1 Fluorogenic labelling of protein in colon cancer cell line
HCT-116 with 3-azido-7-hydroxycoumarin. Imaging of HCT-116 cells
pulse-labelled in media containing 100 mM HPG (top) or 100 mM Met
(bottom). Blue represents coumarin and red represents propidium
iodide (PI) which stains cell nuclei. Scale bar is 50 mm.
Fig. 2 Fluorogenic labelling of ALDH+CD133+ (CSCs) and
ALDHCD133 (non-CSCs) subpopulations in HCT-116 with 3-azido-
7-hydroxycoumarin. CSCs population is isolated based on high ALDH
enzyme activity and surface marker CD133. Double positive
ALDH+CD133+ and negative ALDHCD133 are considered as CSCs
and non-CSCs, respectively. The top panels show fluorescence images of
CSCs (a–c) and non-CSCs (d–f). Proportion of HPG positive cells in the
two populations is shown at the bottom (g). In total more than 300 cells
have been counted in both populations. Cells were treated with 100 mM
HPG for 4 h and L-methionine treated cells were used as control. Scale bar
is 100 mm.
Fig. 3 Flow cytometry histogram of HPG labelling in HCT-116 cells.
Cells were treated with 100 mM HPG (green line) for (a) 2 or (b) 4 h.
L-Met (red histogram) and HPG with protein synthesis inhibitor
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population only overlaps with HPG negative population,
suggesting the CSCs population only co-exists in the HPG
negative population.
In conclusion, bioorthogonal CuAAC reaction (a typical
click chemistry) and homopropargylglycine incorporation has
been used to distinguish CSCs and non-CSCs in a heterogonous
population by controlling the incorporation time of HPG.
Because the slower protein synthesis rate of CSCs, non-CSCs
will be labeled at 2 h incubation while CSCs require more than
4 h. These results reveal the possibility of the rapid protein
profiling of CSCs in heterogonous population. Since our
method utilizes the universal property of CSCs with a lower
rate of cellular protein synthesis, rather than surface proteins
or other biomarkers to differentiate CSCs and non-CSCs, it
has the potential to directly apply to any cancer cell model,
including primary cancer cells.
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